UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Risks of antidepressants during pregnancy: Drugs other than selective serotonin reuptake inhibitors

Authors
Donna Stewart, CM, MD, FRCPC
Simone Vigod, MD, MSc, FRCPC
Section Editors
Peter P Roy-Byrne, MD
Charles J Lockwood, MD, MHCM
Deputy Editor
David Solomon, MD

INTRODUCTION

Pregnant women with psychiatric illnesses are often treated with antidepressant drugs. As an example, studies of pregnant women in Europe have found that antidepressants were used by approximately 3 percent [1-4], and in the United States by 8 percent [5-8]. Compared with selective serotonin reuptake inhibitors (SSRIs), other antidepressants have been used and studied less frequently [1,2,5-12].

Antidepressants cross the placenta and fetal blood brain barrier. Prenatal exposure thus involves potential risks of teratogenesis, preterm birth, low birth weight, and pregnancy complications (eg, spontaneous abortion and postpartum hemorrhage), as well as postnatal effects (eg, persistent pulmonary hypertension of the newborn).

This topic reviews the potential adverse antenatal consequences that may be associated with the use of antidepressant drugs other than SSRIs. The potential adverse effects of using SSRIs during pregnancy, postnatal outcomes among infants exposed in utero to antidepressants, principles of teratology, choice of treatment for depressed pregnant patients, safety of antidepressants in lactating women, and treatment of postpartum depression are discussed separately:

(See "Risks of antidepressants during pregnancy: Selective serotonin reuptake inhibitors (SSRIs)".)

(See "Infants with antenatal exposure to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)".)

                               

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Oct 20 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Petersen I, Gilbert RE, Evans SJ, et al. Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. J Clin Psychiatry 2011; 72:979.
  2. Bakker MK, Kölling P, van den Berg PB, et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008; 65:600.
  3. Munk-Olsen T, Gasse C, Laursen TM. Prevalence of antidepressant use and contacts with psychiatrists and psychologists in pregnant and postpartum women. Acta Psychiatr Scand 2012; 125:318.
  4. Jimenez-Solem E, Andersen JT, Petersen M, et al. Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. PLoS One 2013; 8:e63034.
  5. Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011; 205:51.e1.
  6. Huybrechts KF, Palmsten K, Mogun H, et al. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry 2013; 35:265.
  7. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198:194.e1.
  8. Hayes RM, Wu P, Shelton RC, et al. Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. Am J Obstet Gynecol 2012; 207:49.e1.
  9. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand 2013; 127:94.
  10. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014; 370:2397.
  11. Alwan S, Reefhuis J, Rasmussen SA, et al. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 2011; 51:264.
  12. Nordeng H, van Gelder MM, Spigset O, et al. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012; 32:186.
  13. Palmsten K, Hernández-Díaz S, Huybrechts KF, et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ 2013; 347:f4877.
  14. Hoog SL, Cheng Y, Elpers J, Dowsett SA. Duloxetine and pregnancy outcomes: safety surveillance findings. Int J Med Sci 2013; 10:413.
  15. Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005; 20:327.
  16. Einarson A, Smart K, Vial T, et al. Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report. J Clin Psychiatry 2012; 73:1471.
  17. Kjaersgaard MI, Parner ET, Vestergaard M, et al. Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study. PLoS One 2013; 8:e72095.
  18. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009; 31:403.
  19. Briggs GG, Freeman RK. Venlafaxine. In: Drugs in Pregnancy and Lactation, Wolters Kluwer, Philadelphia 2015. p.1466.
  20. National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance. NICE clinical guideline 192. December 2014. http://www.nice.org.uk/guidance/cg192 (Accessed on October 18, 2015).
  21. Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015; 350:h1798.
  22. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158:1728.
  23. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007; 27:607.
  24. Polen KN, Rasmussen SA, Riehle-Colarusso T, et al. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. Birth Defects Res A Clin Mol Teratol 2013; 97:28.
  25. Palmsten K, Huybrechts KF, Michels KB, et al. Antidepressant use and risk for preeclampsia. Epidemiology 2013; 24:682.
  26. Palmsten K, Setoguchi S, Margulis AV, et al. Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants? Am J Epidemiol 2012; 175:988.
  27. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005; 192:932.
  28. Briggs GG, Freeman RK. Bupropion. In: Drugs in Pregnancy and Lactation, Tenth Edition, Wolters Kluwer, Philadelphia 2015. p.167.
  29. Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010; 203:52.e1.
  30. Louik C, Kerr S, Mitchell AA. First-trimester exposure to bupropion and risk of cardiac malformations. Pharmacoepidemiol Drug Saf 2014; 23:1066.
  31. Cole JA, Modell JG, Haight BR, et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:474.
  32. Stewart DE. Clinical practice. Depression during pregnancy. N Engl J Med 2011; 365:1605.
  33. Briggs GG, Freeman RK. Mirtazapine. In: Drugs in Pregnancy and Lactation, Tenth Edition, Wolters Kluwer, Philadelphia 2015. p.925.
  34. Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006; 67:1280.
  35. Briggs GG, Freeman RK. Trazodone. In: Drugs in Pregnancy and Lactation, Tenth Edition, Wolters Kluwer, Philadelphia 2015. p.1392.
  36. Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003; 48:106.
  37. Briggs GG, Freeman RK. Desipramine. In: Drugs in Pregnancy and Lactation, Tenth Edition, Wolters Kluwer, Philadelphia 2015. p.372.
  38. Briggs GG, Freeman RK. Amitriptyline. In: Drugs in Pregnancy and Lactation, Tenth Edition, Wolters Kluwer, Philadelphia 2015. p.58.
  39. Briggs GG, Freeman RK. Imipramine. In: Drugs in Pregnancy and Lactation, Tenth Edition, Wolters Kluwer, Philadelphia 2015. p.697.
  40. Briggs GG, Freeman RK. Nortriptyline. In: Drugs in Pregnancy and Lactation, Tenth Edition, Wolters Kluwer, Philadelphia 2015. p.1006.
  41. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159:2055.
  42. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339:b3569.
  43. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592.
  44. Vasilakis-Scaramozza C, Aschengrau A, Cabral H, Jick SS. Antidepressant use during early pregnancy and the risk of congenital anomalies. Pharmacotherapy 2013; 33:693.
  45. Ban L, Gibson JE, West J, et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. BJOG 2014; 121:1471.
  46. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40:1723.
  47. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21:157.
  48. Schimmell MS, Katz EZ, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991; 29:479.
  49. Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. Br Med J (Clin Res Ed) 1982; 284:1837.
  50. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159:1889.
  51. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336:258.
  52. Gracious BL, Wisner KL. Phenelzine use throughout pregnancy and the puerperium: case report, review of the literature, and management recommendations. Depress Anxiety 1997; 6:124.
  53. Pavy TJ, Kliffer AP, Douglas MJ. Anaesthetic management of labour and delivery in a woman taking long-term MAOI. Can J Anaesth 1995; 42:618.